MarketScreener Strategies Genmab A/S Nasdaq

Stocks

Real-time Estimate Cboe BZX Other stock markets 05:54:20 18/06/26 am AEST			5-day change	1st Jan Change
25.32 ^USD	+2.36%		+3.18%	-17.95%

15/06	Nordic Equities in North America: Ericsson Slides 1.4 Percent	FW
14/06	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI

	Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis	09 May 2026 at 10:05 pm AEST
	Genmab: 2025 miss and cautious 2026 targets erode investor confidence	19 February 2026 at 01:09 am AEDT
	Genmab advances on earnings strength and pipeline while lower valuation opens upside	08 November 2025 at 02:01 am AEDT
	Genmab: A bold shift from defensive to aggressive	30 September 2025 at 12:45 am AEST
	Genmab: From now on, courage to the most patient	02 April 2025 at 01:57 am AEDT